EW stock: buy or sell?

EW stock price: $245.64 2.11% At close on November 15th, 2019

Updated on:
November 15th, 2019

5

Edwards Lifesciences rose 2.11% to $245.64 after marking all time highs yesterday.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally.

Should I buy EW stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

These 2 buy setups are elegible for Edwards Lifesciences stock now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Edwards Lifesciences stock a buy?

Banks and financial institutions post stock ratings everyday. At Stocks2.com, we detected 15 ratings published for EW stock in the last 30 days.

The general sentiment of these ratings is bullish for EW stock, with 12 positive ratings.
Is EW a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-6Wells Fargo & Con/aOutperform
2019-9-23Piper Jaffray Companiesn/aOverweight
2019-7-25BTIG Researchn/aHold
2019-7-24Wells Fargo & Con/aOutperform
2019-7-24Raymond Jamesn/aOutperform
2019-7-24Raymond Jamesn/aOutperform
2019-7-24Morgan Stanleyn/aOverweight
2019-7-24JPMorgan Chase & Co.n/aNeutral
2019-7-24Jefferies Financial Groupn/aBuy
2019-7-24Credit Suisse Groupn/aOutperform
2019-7-24Canaccord Genuityn/aBuy
2019-7-24BMO Capital Marketsn/aOutperform
2019-7-24Barclaysn/aUnderweight
2019-7-24Bank of AmericaBuyBuy
2019-7-16Morgan Stanleyn/aOverweight

EW stock analysis

Daily outlook

After topping to all time highs yesterday, Edwards Lifesciences rose 2.11% to $245.64.

After topping to all time highs yesterday, Edwards Lifesciences rose 2.11% to $245.64. Since SMA50d and SMA100d crossed up on July, EW price climbed $54.46 per share (28.49%). Yesterday, EW hit a new all time high, pushing higher than on Wednesday tops. Check different trading setups that use ATHs as triggers. On Oct/9 EW price bounced up over the SMA of 50 days demonstrating to be a significant support for this stock.

EW stock chart (daily)

Weekly outlook

Edwards Lifesciences ended this week at $245.64 after marking a new all time high ($245.95) and climbed a brilliant 4.90%. Late September EW rocketed a superb 5.28% in just one week.

Edwards Lifesciences stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, EW might consolidate in a flat-base, waiting to break out over or down under . Late December 2018 EW price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

EW stock chart (weekly)

EW stock price history

EW stock went public on March 27th, 2000 with a price of $3.811. Since then, EW stock grew a 6,347.20%, with an average of 334.10% per year. If you had invested right after EW's IPO a $1,000 in EW stock in 2000, it would worth $63,472.00 today.

1: Adjusted price after possible price splits or reverse-splits.

EW stock historical price chart

EW stock reached all-time highs yesterday with a price of $245.95.

EW stock price target is $227.30

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' EW stock price predictions in the hope that they will be met as they may be wrong and not met. We detected 14 price predictions for EW stock published in the last 30 days:
EW stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-6Wells Fargo & CoRaises Target$220.00$250.0013.6%
2019-9-23Piper Jaffray CompaniesInitiatesn/a$240.00-
2019-7-24Wells Fargo & CoReiterates$207.00$220.006.3%
2019-7-24Raymond JamesReiterates$200.00$232.0016%
2019-7-24Raymond JamesRaises Target$200.00$232.0016%
2019-7-24Morgan StanleyRaises Target$210.00$228.008.6%
2019-7-24JPMorgan Chase & Co.Raises Target$190.00$225.0018.4%
2019-7-24Jefferies Financial GroupReiterates$210.00$245.0016.7%
2019-7-24Credit Suisse GroupReiterates$221.00$226.002.3%
2019-7-24Canaccord GenuityReiterates$215.00$250.0016.3%
2019-7-24BMO Capital MarketsReiterates$204.00$224.009.8%
2019-7-24BarclaysRaises Target$160.00$175.009.4%
2019-7-24Bank of AmericaReiterates$215.00$225.004.7%
2019-7-16Morgan StanleyRaises Target$197.00$210.006.6%
(in average)$203.80$227.3012.0%
The price prediction for Edwards Lifesciences stock is $227.30, moving in a range between $250.00 and $175.00. In average, analysts' outlook on EW price target is positive, increasing the prediction by a 12.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After publishing its last earnings report on April, Edwards Lifesciences . As soon as we get its actual EPS from the earnings report, we will update this review.
EW earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a1.03n/a
2017-Q32017-10-240.860.84-2.3%
2017-Q42018-02-010.910.943.3%
2018-Q12018-04-241.11.2210.9%
2018-Q22018-07-261.131.249.7%
2018-Q32018-10-231.011.075.9%
2018-Q42019-01-311.171.170.0%
2019-Q12019-04-221.23n/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

In 2018, Edwards Lifesciences annual sales soared a shining 8.37% to $3,722.80 M dollars from $3,435.30 marked in 2017. On the other hand, its earnings margin (compared to sales) appreciated to 19.40%, that is $722.20 million.

Edwards Lifesciences fiscal year ends in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Edwards Lifesciences TTM sales up to March 2019 were $3,821.00 and earnings $765.30 million USD. If we compare this TTM figures with the last reported annuality, we can review Edwards Lifesciences business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, gained a slightly fine 2.64%. Regarding profit margin, Edwards Lifesciences remained steady 0.63% to 19.40%

EW annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$2,050 M-$392 M19.1%-
2014$2,323 M13.31%$811 M34.9%107.07%
2015$2,494 M7.35%$495 M19.8%-38.98%
2016$2,964 M18.85%$570 M19.2%15.07%
2017$3,435 M15.91%$584 M17.0%2.48%
2018$3,723 M8.37%$722 M19.4%23.75%
TTM $3,821 M2.64%$765 M20.0%5.97%

Quarterly financial results

Edwards Lifesciences posted $993.00 million in revenues for 2019-Q1, a 1.56% improvement compared to previous quarter. Reported quarter income marked $249.70 million with a profit margin of 25.15%. Profit margin skyrocketed a 24.43% compared to previous quarter when profit margin was 0.72%. When comparing sales to same quarter last year, Edwards Lifesciences sales marked a brilliant growth and boosted a 10.97%. Looking back to recent quarterly results, Edwards Lifesciences posted 2 positive quarters in a row.
EW quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$842 M-$186 M22.1%-
2017-Q3$822 M-2.41%$170 M20.7%-8.60%
2017-Q4$889 M8.16%$-3 M-0.3%-101.65%
2018-Q1$895 M0.71%$207 M23.1%-7,478.57%
2018-Q2$944 M5.46%$283 M30.0%36.83%
2018-Q3$907 M-3.93%$226 M24.9%-20.09%
2018-Q4$978 M7.84%$7 M0.7%-96.90%
2019-Q1$993 M1.56%$250 M25.1%3,467.14%

Edwards Lifesciences ownership

When you are planning to buy a stock, it's worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Edwards Lifesciences, 3.94% of all outstanding shares are owned by its staff.

In case of Edwards Lifesciences stock, 0.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for EW stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Edwards Lifesciences:

EWBSXCRYICUILMAT
Market cap$51.2 B$58.8 B$941.6 M$3.6 B$682.4 M
Total shares208.6 M1,390.0 M37.5 M20.7 M19.9 M
Float shares207.1 M1,390.0 M36.0 M19.2 M16.2 M
  - Institutional holdings (%)0.0%93.4%72.1%93.5%77.8%
  - Insider holdings (%)3.9%0.2%3.8%7.1%18.5%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

EW summary

Friday, November 15th, 2019
Open$242.14
Close$245.64
Day range$241.54 - $245.95
Previous close$240.56
Session gain2.11%
Average true range$4.28
50d mov avg$226.74
100d mov avg$216.95
200d mov avg$198.38
Daily pattern
Weekly pattern lt06a

Edwards Lifesciences performance

To better understand Edwards Lifesciences performance you must becnhmark its gains with other related stocks in same sector or industry. For Edwards Lifesciences, the benchmark is made against Boston Scientific, CryoLife, ICU Medical, LeMaitre Vascular, Medtronic and Merit Medical Systems.
Stock3m6m12m
EWEdwards Lifescien...11.99%41.89%57.75%
BSXBoston Scientific0.38%13.37%13.71%
CRYCryoLife-4.85%-14.27%-15.57%
ICUIICU Medical5.09%-22.33%-28.06%
LMATLeMaitre Vascular9.39%25.70%26.07%
MDTMedtronic9.60%29.09%22.22%
MMSIMerit Medical Sys...-26.92%-51.83%-56.85%

Edwards Lifesciences competitors

One check before trading any stock is to review a list of its competitors, in this case for Edwards Lifesciences. We chose 6 companies as Edwards Lifesciences competitors as they are in the same industry or have similar market objectives.

Latest EW stock news